1. Hartman J, Patki T, Johnson NE. Diagnosis and management of myotonic dystrophy type 1. JAMA. 2024;331(14):1227-1228. doi:10.1001/jama.2024.2511
2. Ikeda KS, Iwabe-Marchese C, França Jr MC, Nucci A, de Carvalho KM. Myotonic dystrophy type 1: frequency of ophthalmologic findings. Arq Neuropsiquiatr. 2016;74(3):183-188. doi:10.1590/0004-282X20150218
3. Bird TD. Myotonic Dystrophy Type 1. University of Washington, Seattle, Seattle (WA); 1993.
4. Chahine M, Ginjupalli VKM, Jauvin D, Boutjdir M. Therapeutic strategies targeting the molecular pathogenesis of myotonic dystrophy type 1: current status and future directions. Mol Diagn Ther. 2026. doi:10.1007/s40291-026-00848-3
5. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81(4):358-367. doi:10.1136/jnnp.2008.158261
6. Rahm L, Hale MA, Raaijmakers RHL, et al. Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives. Nat Rev Neurol. 2025;21(11):623-641. doi:10.1038/s41582-025-01139-x
7. Abed E, D’Amico G, Rossi S, Perna A, Bianchi MLE, Silvestri G. Spectral domain optical coherence tomography findings in myotonic dystrophy. Neuromuscular Disorders. 2020;30(2):144-150. doi:10.1016/j.nmd.2019.11.012
8. Vasilijevic J, Peric S, Basta I, et al. Retinal vascular abnormalities in myotonic dystrophy assessed by optical coherence tomography angiography-cross-sectional study. Eur J Ophthalmol. 2025;35(1):262-268. doi:10.1177/11206721241247424
9. Akan O, Erden B. Optical coherence tomography findings in patients with myotonic dystrophy type 1. Eur Arch Med Res. 2021;37(3):178-182. doi:10.4274/eamr.galenos.2021.53315
10. Ginjupalli VKM, Reisqs JB, Cupelli M, Chahine M, Boutjdir M. Cardiac involvement in myotonic dystrophy type 1: mechanisms, clinical perspectives, and emerging therapeutic strategies. Int J Mol Sci. 2025; 26(22):10992. doi:10.3390/ijms262210992